These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 22659488)

  • 1. Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.
    García-Arriaza J; Arnáez P; Jiménez JL; Gómez CE; Muñoz-Fernández MÁ; Esteban M
    Virus Res; 2012 Aug; 167(2):391-6. PubMed ID: 22659488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.
    Gómez CE; Nájera JL; Perdiguero B; García-Arriaza J; Sorzano CO; Jiménez V; González-Sanz R; Jiménez JL; Muñoz-Fernández MA; López Bernaldo de Quirós JC; Guardo AC; García F; Gatell JM; Plana M; Esteban M
    J Virol; 2011 Nov; 85(21):11468-78. PubMed ID: 21865377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
    García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
    J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
    Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
    J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
    García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
    PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
    Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
    PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
    García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
    PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.
    Vijayan A; García-Arriaza J; Raman SC; Conesa JJ; Chichón FJ; Santiago C; Sorzano CÓ; Carrascosa JL; Esteban M
    PLoS One; 2015; 10(7):e0133595. PubMed ID: 26208356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
    García-Arriaza J; Nájera JL; Gómez CE; Sorzano CO; Esteban M
    PLoS One; 2010 Aug; 5(8):e12395. PubMed ID: 20811493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.
    Gómez CE; Nájera JL; Sánchez R; Jiménez V; Esteban M
    Vaccine; 2009 May; 27(24):3165-74. PubMed ID: 19446187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
    Perdiguero B; Gómez CE; Nájera JL; Sorzano CO; Delaloye J; González-Sanz R; Jiménez V; Roger T; Calandra T; Pantaleo G; Esteban M
    PLoS One; 2012; 7(10):e48524. PubMed ID: 23119046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India.
    Kumar S; Aggarwal P; Vajpayee M; Pandey RM; Seth P
    Vaccine; 2006 Mar; 24(14):2585-93. PubMed ID: 16480792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.
    Guerra S; González JM; Climent N; Reyburn H; López-Fernández LA; Nájera JL; Gómez CE; García F; Gatell JM; Gallart T; Esteban M
    J Virol; 2010 Aug; 84(16):8141-52. PubMed ID: 20534857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.
    Gómez CE; Perdiguero B; García-Arriaza J; Cepeda V; Sánchez-Sorzano CÓ; Mothe B; Jiménez JL; Muñoz-Fernández MÁ; Gatell JM; López Bernaldo de Quirós JC; Brander C; García F; Esteban M
    PLoS One; 2015; 10(11):e0141456. PubMed ID: 26544853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.